RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis

Bomi Lee, Urszula T. Iwaniec, Russell T. Turner, Yi Wei Lin, Bart Clarke, Anne Gingery, Li Na Wei

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage-specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.

Original languageEnglish (US)
Pages (from-to)e90517
JournalJCI insight
Volume2
Issue number7
DOIs
StatePublished - Apr 6 2017

Fingerprint

Nuclear Receptor Co-Repressor 1
Osteoclasts
Monocytes
Homeostasis
Macrophages
Bone and Bones
Nuclear Receptor Subfamily 2, Group C, Member 2
Osteoblasts
Bone Diseases
Osteogenesis
Protein Precursors
Bone Resorption
Conditioned Culture Medium
Proteolysis
Osteoporosis

Cite this

RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. / Lee, Bomi; Iwaniec, Urszula T.; Turner, Russell T.; Lin, Yi Wei; Clarke, Bart; Gingery, Anne; Wei, Li Na.

In: JCI insight, Vol. 2, No. 7, 06.04.2017, p. e90517.

Research output: Contribution to journalArticle

Lee, Bomi ; Iwaniec, Urszula T. ; Turner, Russell T. ; Lin, Yi Wei ; Clarke, Bart ; Gingery, Anne ; Wei, Li Na. / RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. In: JCI insight. 2017 ; Vol. 2, No. 7. pp. e90517.
@article{761d35dfd30b487794d9ada7239ceb33,
title = "RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis",
abstract = "Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage-specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.",
author = "Bomi Lee and Iwaniec, {Urszula T.} and Turner, {Russell T.} and Lin, {Yi Wei} and Bart Clarke and Anne Gingery and Wei, {Li Na}",
year = "2017",
month = "4",
day = "6",
doi = "10.1172/jci.insight.90517",
language = "English (US)",
volume = "2",
pages = "e90517",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis

AU - Lee, Bomi

AU - Iwaniec, Urszula T.

AU - Turner, Russell T.

AU - Lin, Yi Wei

AU - Clarke, Bart

AU - Gingery, Anne

AU - Wei, Li Na

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage-specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.

AB - Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage-specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.

UR - http://www.scopus.com/inward/record.url?scp=85041079906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041079906&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.90517

DO - 10.1172/jci.insight.90517

M3 - Article

C2 - 28405613

AN - SCOPUS:85041079906

VL - 2

SP - e90517

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 7

ER -